杜邦加大工业生物投资——7500万美元收购Dyadic酶技术资产

发布时间：2018-07-02 10:16

  本文选题：Dyadic + 酶技术　； 参考：《印染》2015年24期

【摘要】：正年月号,杜邦生物科技(Biosciences)与Dyadic公司签署协议,杜邦以7 500万美元收购Dyadic的酶技术及产品。其中包括Dyadic的C1技术平台(一项真菌表达酶的技术)及广泛应用的液体和干酶制剂。此举将进一步扩大杜邦工业生物技术在全球的领头羊地位。"C1平台将补充杜邦世界级的酶表达系统,将为我们强大的创新渠道推向市场提供更多的操作灵活性,"杜邦工业生物科技总裁William F.Feehery称。"此外,随着收购Dyadic的商品酶组合,我们期待服务新的客户,并为动物营养、食
[Abstract]:DuPont signed an agreement with Dyadic on the date of the year, DuPont bought Dyadic's enzyme technology and products for $75 million, including the Dyadic C1 technology platform (a fungal expression enzyme technology) and the widely used liquid and dry enzyme preparations. This will further expand DuPont industrial biotechnology in the world's lead. "The C1 platform will complement DuPont's world-class enzyme expression system that will provide more operational flexibility for our powerful innovative channels to market," said DuPont industrial biotechnology President William F.Feehery. "In addition, with the purchase of Dyadic's commercial enzyme combination, we look forward to serving new customers and feeding on animal nutrition.
【分类号】：F416.7
，

本文编号：2089795